Injectable silicone implants as vaccine delivery vehicles

Vaccine

Volumn 20, Issue 13-14, 2002, Pages 1725-1732

  Lofthouse, S A ^a   Kajihara, M ^b   Nagahara, S ^b   Nash, A ^c   Barcham, G J ^a   Sedgmen, B ^a   Brandon, M R ^a   Sano, A ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c Zenyth Therapeutics Limited Australia   (Australia)

Author keywords

Controlled release; Implant; Tetanus; Vaccination; Vaccine delivery

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; ANTIGEN; AVIDIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOPURE; INTERLEUKIN 1BETA; ORGANIC SOLVENT; SILICONE; TETANUS TOXIN; TOXOID; VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLOSTRIDIUM; CLOSTRIDIUM NOVYI; CLOSTRIDIUM TETANI; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG RESPONSE; FEMALE; FREEZE DRYING; IMMUNOGLOBULIN PRODUCTION; IMPLANTATION; IN VITRO STUDY; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; SHEEP; SILICONE PROSTHESIS; TEMPERATURE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIGENS; AVIDIN; CLOSTRIDIUM; CLOSTRIDIUM TETANI; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; FEMALE; INTERLEUKIN-1; MALE; RECOMBINANT PROTEINS; SHEEP; SILICONES; TETANUS TOXOID; TOXOIDS; VACCINES;

EID: 0037086497     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00036-1     Document Type: Article

References (22)

1. Maintenance of in vivo tolerance by persistence of antigen
2. Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance
3. The effects of continuous and intermittent delivery of antigens of Boophilus microplus on the development of murine antibodies
4. Biodegradable implants for the delivery of veterinary vaccines: Design, manufacture and antibody responses in sheep
5. A single-step immunization by sustained antigen release
6. Development of new drug delivery system for protein drugs using silicone(I)
7. Controlled release system as novel vaccination method
8. Continuous antigen delivery from controlled release implants elicits significant and anamnestic immune responses
9. Production and in vivo use of recombinant ovine interleukin-1 as an immunological adjuvant
10. Future prospects for vaccine adjuvants
11. Advances in adjuvant technology and applications
12. Recombinant ovine interleukin-1β as an adjuvant for multivalent bacterial vaccines
13. Adjuvants: A classification and review of the mode of action
14. Vaccine adjuvants
15. Specific inhibition of antibody production. Part I. Protein overloading paralysis
16. Specific inhibition of antibody production. Part II. Paralysis induced in adult mice by small quantities of protein antigen
17. Induction of immunological paralysis in two zones of dosage
18. Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous or intradermal route
19. Parameters related to the application of recombinant ovine interleukin-1β as a vaccine adjuvant
20. Homeostasis and self-tolerance in the immune system; turning lymphocytes off